AstraZeneca settles dispute with Accord and Intas - MarketWatch

LONDON -(MarketWatch)- AstraZeneca PLC (AZN.LN), a global biopharmaceutical company announced Wednesday it has entered into a settlement agreement in its U.S. SEROQUEL XR patent infringement litigation against Accord Healthcare, Inc. and Intas Pharmaceuticals Ltd regarding Accord's proposed generic version of AstraZeneca's SEROQUEL XR (quetiapine fumarate) extended-release tablets.